NasdaqCM:PIRS

Stock Analysis Report

Executive Summary

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Pieris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.0%

PIRS

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-39.4%

PIRS

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: PIRS underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: PIRS underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

PIRSIndustryMarket
7 Day-4.0%1.6%0.4%
30 Day-40.3%-2.4%-1.2%
90 Day-31.2%-1.5%-0.4%
1 Year-39.4%-39.4%-6.9%-7.7%9.3%6.9%
3 Year94.4%94.4%14.7%10.7%45.8%36.4%
5 Yearn/a-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is Pieris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pieris Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

7.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PIRS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PIRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate PIRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PIRS is overvalued based on its PB Ratio (8x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Pieris Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-3.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PIRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PIRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PIRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PIRS's revenue (31.3% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: PIRS's revenue (31.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if PIRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Pieris Pharmaceuticals performed over the past 5 years?

-19.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PIRS is unprofitable, and losses have increased over the past 5 years at a rate of -19.2% per year.

Accelerating Growth: Unable to compare PIRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PIRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: PIRS has a negative Return on Equity (-204.99%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PIRS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PIRS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Pieris Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PIRS's short term assets ($111.5M) exceeds its short term liabilities ($40.9M)

Long Term Liabilities: PIRS's short term assets (111.5M) exceeds its long term liabilities (70.4M)


Debt to Equity History and Analysis

Debt Level: PIRS is debt free.

Reducing Debt: PIRS currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: PIRS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PIRS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PIRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PIRS has sufficient cash runway for 2.049858 years if free cash flow continues to reduce at historical rates of -25.2% each year.


Next Steps

Dividend

What is Pieris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PIRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PIRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PIRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PIRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PIRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Pieris Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Steve Yoder (43yo)

4.8yrs

Tenure

US$2,621,008

Compensation

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as  ...


CEO Compensation Analysis

Compensation vs. Market: Steve's total compensation ($USD2.62M) is about average for companies of similar size in the US market ($USD1.16M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.0yrs

Average Tenure

44.5yo

Average Age

Experienced Management: PIRS's management team is not considered experienced ( 2 years average tenure), which suggests a new team.


Board Age and Tenure

1.8yrs

Average Tenure

58yo

Average Age

Experienced Board: PIRS's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$224,97010 Sep 19
BVF Partners LP
EntityCompany
Shares50,000
Max PriceUS$4.50

Ownership Breakdown


Management Team

  • Louis Matis (68yo)

    Senior VP & Chief Development Officer

    • Tenure: 4.2yrs
    • Compensation: US$1.12m
  • Claus Schalper

    Co-Founder & Senior Advisor

    • Tenure: 2.2yrs
  • Steve Yoder (43yo)

    CEO, President & Director

    • Tenure: 4.8yrs
    • Compensation: US$2.62m
  • Allan Reine (44yo)

    • Tenure: 0.08yrs
    • Compensation: US$871.26k
  • Christine Rothe

    Head of Discovery & Alliance Management and VP

    • Tenure: 0yrs
  • Ahmed Mousa

    VP, General Counsel & Corporate Secretary

    • Tenure: 2.4yrs
  • Frank Vollmering

    Vice President of Human Resources

    • Tenure: 1.8yrs
  • Maria Kelman

    Director of Investor Relations

    • Tenure: 0yrs
  • Hitto Kaufmann

    Senior VP & Chief Scientific Officer

    • Tenure: 0.2yrs
  • Tom Bures (45yo)

    Principal Financial & Accounting Officer and Treasurer

    • Tenure: 0.08yrs

Board Members

  • Jim Geraghty (64yo)

    Chairman

    • Tenure: 1.8yrs
    • Compensation: US$199.86k
  • Michael Richman (58yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$144.40k
  • Chris Kiritsy (54yo)

    Director

    • Tenure: 3.1yrs
    • Compensation: US$152.76k
  • Peter Kiener (67yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$105.52k
  • Matt Sherman (63yo)

    Director

    • Tenure: 1yrs
    • Compensation: US$99.96k
  • Steve Yoder (43yo)

    CEO, President & Director

    • Tenure: 4.8yrs
    • Compensation: US$2.62m
  • Ann Barbier (55yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$154.03k
  • Jean-Pierre Bizzari (65yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$139.95k
  • Maya Said (42yo)

    Director

    • Tenure: 0.2yrs

Company Information

Pieris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pieris Pharmaceuticals, Inc.
  • Ticker: PIRS
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$155.587m
  • Shares outstanding: 49.39m
  • Website: https://www.pieris.com

Number of Employees


Location

  • Pieris Pharmaceuticals, Inc.
  • 255 State Street
  • 9th Floor
  • Boston
  • Massachusetts
  • 2109
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PIRSNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDDec 2014
PI6DB (Deutsche Boerse AG)YesNew Common StockDEEURDec 2014

Biography

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:25
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.